RSS Content

AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook
  • Revenue of $29.9 million – up 20.3% as reported, 24% constant currency
  • U.S. sales of $22.9 million – up 26.3%
  • International sales of $7.0 million – up 3.9% as reported, 17.6% constant currency

WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, today announced first quarter 2015 financial results.

“We had a strong start to the year and remain well positioned to help treat patients suffering from atrial fibrillation through our continued investment in education, training and growth initiatives,” said Mike Carrel, President and Chief Executive Officer of AtriCure.

“We are particularly excited about partnering with the American Association for Thoracic Surgery (AATS) Graham Foundation to initiate the inaugural Dr. James Cox Fellowship in Atrial Fibrillation Surgery. Educational efforts such as this will increase awareness and the ability of physicians to treat atrial fibrillation and manage the left atrial appendage. We continue to work toward penetrating the multi-billion dollar market opportunity ahead of us, which is increasingly being validated by leading physicians,” continued Mr. Carrel.

First Quarter 2015 Financial Results

Revenue for the first quarter of 2015 was $29.9 million, an increase of $5.0 million or 20.3% (24.0% on a constant currency basis), compared to first quarter 2014 revenue. Domestic revenue increased 26.3% to $22.9 million, driven by strong sales of ablation-related open-heart products, ablation-related minimally invasive products, and AtriClip products. International revenue was $7.0 million, an increase of $0.3 million or 3.9% (17.6% on a constant currency basis) compared to $6.7 million for the first quarter of 2014. International revenue growth was driven primarily by increases in product sales in Europe.

Gross profit for the first quarter of 2015 was $21.7 million compared to $17.7 million for the first quarter of 2014. Gross margin for the first quarter of 2015 and 2014 was 72.7% and 71.1%, respectively. The increase in gross margin was primarily due to the heavier U.S. sales mix, favorable product costs and the elimination of certain acquisition transition costs included in the three months ended March 31, 2014.

Operating expenses for the first quarter of 2015 increased 5.1%, or $1.3 million, compared to the first quarter of 2014. The increase in operating expenses was driven primarily by an increase in selling, clinical, product development, and training expenses partially offset by certain acquisition transition costs included in the three months ended March 31, 2014.

Loss from operations for the first quarter of 2015 was $5.1 million, compared to $7.9 million for the first quarter of 2014. Adjusted EBITDA, a non-GAAP measure, was a loss of $2.1 million for the first quarter of 2015, compared to a $4.7 million loss for the first quarter of 2014. Net loss per share was $0.19 for the first quarter of 2015 and $0.31 for the first quarter of 2014.

2015 Guidance

Management projects that 2015 revenue will be in the range of $123.5 million to $125.5 million, which represents an increase of 15% to 17% over 2014 (17% to 19% on a constant currency basis). This compares to previous expectations of 2015 revenue in the range of $122.5 million to $124.5 million.

Management continues to project Adjusted EBITDA, a non-GAAP measure, to be a loss in the range of $7 million to $9 million for 2015 in order to continue making strategic investments to drive the long-term growth plan.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2015 to discuss its first quarter 2015 financial results. A live webcast of the conference call will be available online on the Investors page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an operator by calling (866) 515-2911 for domestic callers and (617) 399-5125 for international callers at least 15 minutes prior to the call start time using participant passcode 15114945.

The webcast will be available on AtriCure’s website and a telephonic replay of the call will be available through May 6, 2015. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. The participant passcode is 62321731.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 33 million people worldwide.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates (including projections and guidance), other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, AtriCure’s ability to retain and attract key employees, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, AtriCure’s ability to continue to be in compliance with applicable U.S. federal and state and foreign government laws and regulations, AtriCure’s ability to consummate acquisitions or, if consummated, to successfully integrate acquired businesses into AtriCure’s operations, AtriCure’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings, failure of an acquisition or acquired company to achieve its plans and objectives generally, risk that proposed or consummated acquisitions may disrupt operations or pose difficulties in employee retention or otherwise affect financial or operating results, competition from existing and new products and procedures, including the development of drug or catheter-based technologies, or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, fluctuations in exchange rates for future sales denominated in foreign currency, which represent a majority of AtriCure’s sales outside of the United States, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure uses certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures provide an indication of performance excluding certain items. Our management believes that in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing operations and our management believes that the excluded items are typically not reflective of our ongoing core business operations. Further, management uses results of operations before these excluded items as a basis for its strategic planning. The non-GAAP financial measures used by AtriCure may not be the same or calculated the same as those used by other companies. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP.

ATRICURE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts)
(Unaudited)
   
 
Three Months Ended March 31,
2015 2014
 
Domestic Revenue:
Open-heart ablation $ 12,354 $ 10,377
Minimally invasive ablation 4,347 3,448
AtriClip   5,503     3,620  
Total ablation and AtriClip 22,204 17,445
Valve tools   719     698  
Total domestic 22,923 18,143
 
International Revenue:
Open-heart ablation 4,216 3,971
Minimally invasive ablation 1,968 2,003
AtriClip   671     443  
Total ablation and AtriClip 6,855 6,417
Valve tools   108     287  
Total international 6,963 6,704
 
Total revenue 29,886 24,847
Cost of revenue   8,151     7,190  
Gross profit 21,735 17,657
 
Operating expenses:
Research and development expenses 5,609 4,001
Selling, general and administrative expenses   21,270     21,581  
Total operating expenses   26,879     25,582  
 
Loss from operations (5,144 ) (7,925 )
 
Other (expense) income, net   (116 )   243  
 
Loss before income tax expense (5,260 ) (7,682 )
 
Income tax expense   6     27  
 
Net loss $ (5,266 ) $ (7,709 )
 
Basic and diluted net loss per share $ (0.19 ) $ (0.31 )
 

Weighted average shares used in computing net loss per share:

Basic and diluted   27,069     24,766  
 
ATRICURE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Per Share Amounts)
(Unaudited)
   
March 31, December 31,
2015 2014
Assets
 
Current assets:
Cash, cash equivalents and short-term investments $ 55,733 $ 59,649
Accounts receivable, net 19,786 17,558
Inventories 15,106 14,257
Other current assets   2,790     2,044  
Total current assets 93,415 93,508
 
Property and equipment, net 13,874 11,552
Long-term investments 2,025 8,894
Goodwill and intangible assets, net 43,961 44,264
Other noncurrent assets   131     186  
Total assets $ 153,406   $ 158,404  
 
Liabilities and Stockholders' Equity
 
Current liabilities:
Accounts payable and accrued liabilities $ 18,633 $ 21,662
Other current liabilities and current maturities of capital leases   5,996     3,981  
Total current liabilities 24,629 25,643
 
Capital leases 79 74
Other noncurrent liabilities   139     149  
Total liabilities 24,847 25,866
 
Stockholders' equity:
Common stock 28 28
Additional paid-in capital 273,019 271,282
Accumulated other comprehensive loss (798 ) (348 )
Accumulated deficit   (143,690 )   (138,424 )
Total stockholders' equity 128,559 132,538
   
Total liabilities and stockholders' equity $ 153,406   $ 158,404  
 
ATRICURE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)
   
Three Months Ended March 31,
2015 2014
 
Cash flows from operating activities:
Net loss $ (5,266 ) $ (7,709 )

Adjustments to reconcile net loss to net cash used in operating activities:

Share-based compensation expense 1,724 2,142
Depreciation and amortization of intangible assets 1,311 1,085
Amortization of deferred financing costs 16 59
Loss on disposal of property and equipment 57 14
Realized loss from foreign exchange on intercompany transactions 251 -
Amortization/accretion on investments 184 83
Change in allowance for doubtful accounts 100 (17 )
Other - 95
Changes in operating assets and liabilities
Accounts receivable (2,685 ) (1,045 )
Inventories (1,104 ) (862 )
Other current assets (779 ) 312
Accounts payable and accrued liabilities (2,807 ) (8,500 )
Other non-current assets and liabilities   28     (55 )
Net cash used in operating activities (8,970 ) (14,398 )
 
Cash flows from investing activities:
Purchases of available-for-sale securities (6,086 ) -
Sales and maturities of available-for-sale securities 11,899 8,434
Purchases of property and equipment (1,434 ) (1,020 )
Increases in property under build-to-suit obligation   (1,822 )   -  
Net cash provided by investing activities 2,557 7,414
 
Cash flows from financing activities:
Net proceeds from sale of stock - 65,872
Payments on debt and capital leases (14 ) (6,343 )
Increases in build-to-suit obligation 1,822 -
Payment of debt fees and premium on retirement of debt - (100 )
Proceeds from stock option exercises 516 1,395
Shares repurchased for payment of taxes on stock awards   (503 )   (88 )
Net cash provided by financing activities 1,821 60,736
 
Effect of exchange rate changes on cash and cash equivalents   (233 )   (5 )
 
Net (decrease) increase in cash and cash equivalents (4,825 ) 53,747
Cash and cash equivalents - beginning of period   28,384     14,892  
Cash and cash equivalents - end of period $ 23,559   $ 68,639  
 
Supplemental cash flow information:
Cash paid for interest $ 2 $ 102
Cash paid for income taxes - 146
Noncash investing and financing activities:
Accrued purchases of property and equipment 751 124
Assets acquired through capital lease 36 -
 
ATRICURE, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS
(In Thousands)
(Unaudited)
   
 
Reconciliation of Non-GAAP Adjusted Loss (Adjusted EBITDA)
 
Three Months Ended March 31,
2015 2014
 
Net loss, as reported $ (5,266 ) $ (7,709 )
Income tax expense 6 27
Other expense (income), net (a) 116 (243 )
Depreciation and amortization expense 1,311 1,085
Share-based compensation expense   1,724     2,142  
Non-GAAP adjusted loss (adjusted EBITDA) $ (2,109 ) $ (4,698 )
 
 
Three Months Ended March 31,
(a) Other includes: 2015 2014
 
Net interest income (expense) $ 25 $ (223 )
Grant income 35 363
(Loss) gain due to exchange rate fluctuation (163 ) 5
Non-employee stock option (expense) income   (13 )   98  
Other (expense) income, net $ (116 ) $ 243  
 

Source: AtriCure, Inc.

AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President and Chief Financial Officer
awade@atricure.com
or
Investor Relations Contact
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com